JSPR Stock Analysis: Buy, Sell, or Hold?
JSPR - Jasper Therapeutics, Inc. Common Stock
$0.98
-0.07 (-6.95%)
▼
5d:
-17.89%
30d:
-29.2%
90d:
-44.49%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 02, 2026
2d
Get Alerted When JSPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: JSPR is down 17.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: JSPR is down 17.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: JSPR is currently trading at $0.98, which is considered oversold relative to its 30-day fair value range of $1.16 to $1.39.
Technical Outlook: Technically, JSPR is in a strong downtrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: JSPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $8.70 (+728.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JSPR is in a strong downtrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: JSPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $8.70 (+728.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.16 -
$1.39
Company Quality Score
46/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 728.6% below Wall St target ($8.70)
Fair Price Analysis
30-Day Fair Range
$1.16 -
$1.39
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.60
(60.9%)
Support & Resistance Levels
Support Level
$1.01
Resistance Level
$1.27
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.44
Wall Street Target
$8.70
(+728.6%)
Share & Embed Analysis
Last updated: March 30, 2026 1:41 PM ET
Data refreshes hourly during market hours. Next update: 2:41 PM
Data refreshes hourly during market hours. Next update: 2:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JSPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
